Company news

Anatara Lifesciences Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Change of Registry Address Notification

October 26, 2026

Notice of Annual General Meeting/Proxy Form

October 22, 2026

Appendix 4G & Corporate Governance Statement

October 22, 2026

Annual Report to shareholders

October 22, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 12, 2026

Date of 2026 Annual General Meeting

September 23, 2026

Anatara receives $318,402 in R&D Tax Incentive for FY26

September 14, 2026

Change of Director's Interest Notice

August 24, 2026

Application for quotation of securities - ANR

August 24, 2026

Conversion of Performance Rights and Cleansing Notice

August 24, 2026

Appendix 4E & Financial Report 30 June 2026

August 18, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 31, 2026

Appendix 4D & Half Year Report 31 December 2025

February 25, 2026

Company Update

February 18, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Anatara receives firm commitments for $1.2m Placement

October 1, 2025

Trading Halt

September 28, 2025

Response to ASX Price Query

September 5, 2025

Pause in Trading

September 5, 2025

Appendix 4E & Financial Report 30 June 2025

August 13, 2025

Anatara receives $969,455 in R&D Tax Incentive for FY25

July 28, 2025

Hong Kong Patent Granted for GaRP

May 19, 2025

Phase II GaRP-IBS Trial Internal Analyses of Data Subsets

May 15, 2025

Funding Advance on R&D Refund

April 30, 2025

Phase II GaRP-IBS Trial Headline Analysis of Results

April 17, 2025

Phase II GaRP-IBS Trial & Anti-Obesity Project Updates

March 9, 2025

Appendix 4D & Half Year Report 31 December 2024

February 25, 2025

Australian Patent Granted for GaRP Product

January 28, 2025

GaRP-IBS Clinical Trial Update

December 12, 2024

Share Purchase Plan Offer Booklet

November 26, 2024

Successful Placement of $660k and Share Purchase Plan

November 15, 2024

Chair's Address to Shareholders

November 14, 2024

Appendix 4C & Q1 FY25 Activities Report

October 31, 2024

GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update

October 7, 2024

Anatara's GaRP granted EU patent

September 20, 2024

GaRP Irritable Bowel Syndrome Clinical Trial Update

August 29, 2024

$626,000 received in R&D Tax Incentive for FY24

August 28, 2024

Appendix 4E & Financial Report 30 June 2024

August 22, 2024

Appendix 4C & Q4 FY24 Activities Report

July 30, 2024

Anatara successful placement for $1.0M

May 1, 2024

Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2

February 29, 2024

Appendix 4D & Half Year Report 31 December 2023

February 28, 2024

Appendix 4C & Q2 FY24 Activities Report

January 23, 2024

Entitlement Offer Results

December 6, 2023

Non-Renounceable Entitlement Offer Booklet

November 13, 2023

Entitlement offer opens and dispatch of Offer Booklet

November 13, 2023

AGM Chair Address

November 9, 2023

GaRP Clinical Trial AGM Presentation

November 9, 2023

Cleansing Notice

November 2, 2023

Anatara launches a partially underwritten Entitlement Offer

November 2, 2023

Older news releases →

Decks

The 5 newest of 35 decks. Every deck is listed under its year.